Cargando…

Role of IRF4 in resistance to immunomodulatory (IMid) compounds(®) in Waldenström’s macroglobulinemia

BACKGROUND: Immunomodulatory drugs, IMid compounds, are active in Waldenström's macroglobulinemia (WM), although in a lesser extent than multiple myeloma, where it was initially developed. We hypothesized WM tumour cells might develop mechanisms of resistance, and sought to identify and describ...

Descripción completa

Detalles Bibliográficos
Autores principales: Bertrand, Elisabeth, Jouy, Nathalie, Manier, Salomon, Fouquet, Guillemette, Guidez, Stéphanie, Boyle, Eileen, Noel, Stéphanie, Tomowiak, Cécile, Herbaux, Charles, Schraen, Susanna, Preudhomme, Claude, Quesnel, Bruno, Poulain, Stéphanie, Leleu, Xavier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762562/
https://www.ncbi.nlm.nih.gov/pubmed/29348877
http://dx.doi.org/10.18632/oncotarget.22872
Descripción
Sumario:BACKGROUND: Immunomodulatory drugs, IMid compounds, are active in Waldenström's macroglobulinemia (WM), although in a lesser extent than multiple myeloma, where it was initially developed. We hypothesized WM tumour cells might develop mechanisms of resistance, and sought to identify and describe these mechanisms. MATERIAL AND METHOD: MM and WM-derived cell lines, and Waldenström's CD19+ cells were treated using both lenalidomide and pomalidomide. Stable CRBN expressing cells were generated. RESULTS: WM-derived cells were resistant to IMid compounds. We demonstrated a modulation of the downstream targets of IRF4, despite low expression of cereblon, and hypothesized IRF4 was the cause for resistance to IMid compounds. We ruled out the role of various IRF4 regulatory mechanisms, and other pathways activating WM tumor cells, such as B cell activators. CONCLUSION: This study demonstrated that mechanisms of resistance to IMid compounds could be not related to cereblon. IRF4 was identified as the potential mechanism of resistance to lenalidomide and pomalidomide in WM. It potentially explains the lesser activity observed in the clinic in WM. Interestingly, some WM patients benefited strongly to lenalidomide and pomalidomide, and future studies will have to describe the indirect mechanisms of IMid compounds in WM, possibly related to an immune-mediated process.